Company profile: RhoVac
1.1 - Company Overview
Company description
- Provider of an immuno-oncology therapeutic cancer vaccine targeting metastatic cancer cells by recognizing RhoC-overexpressing cells to stimulate an immune response (RV001, in clinical trials), plus oncology technologies: iCIP (LiPlaCis + DRP to identify cisplatin responders and deliver the drug with higher efficacy and less toxicity), LiPlaCis (liposomal cisplatin), and DRP (mRNA-based predictor of cisplatin response).
Products and services
- DRP®: A multigene mRNA-based Drug-specific Response Predictor that assesses tumor-biopsy gene expression to gauge a patient's likelihood of responding to cisplatin therapy
- ICIP™: An integrated combination of LiPlaCis® and DRP® that identifies cisplatin-benefiting patients and coordinates drug delivery to achieve higher efficacy with reduced toxicity
- LiPlaCis®: A liposomal cisplatin formulation engineered to target cancer cells more effectively and lessen side effects compared to conventional cisplatin
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to RhoVac
Quest PharmaTech
HQ: Canada
Website
- Description: Provider of antibody-based immunotherapeutic products for cancer and photodynamic therapy technology for oncology and dermatology, including Oregovomab, an antibody-based immunotherapy in clinical trials for ovarian cancer, and truncated MUC16-targeting Mab AR 9.6 as a theranostic agent.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Quest PharmaTech company profile →
Trubion
HQ: United States
Website
- Description: Provider of biopharmaceutical product candidates for autoimmune diseases and cancer, developing novel single-chain polypeptide proteins built with its SMIP custom drug assembly technology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Trubion company profile →
MBrace Therapeutics
HQ: United States
Website
- Description: Provider of biopharmaceutical oncology solutions, including MBRC-101, an antibody-drug conjugate targeting the EphA5 receptor for solid tumors such as breast and lung cancer; SPARTA, a proprietary platform to identify new cancer targets and accelerate ADC development; and a Phase 1/1b clinical trial of MBRC-101 evaluating safety, tolerability, and preliminary efficacy in advanced metastatic solid tumors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MBrace Therapeutics company profile →
Adaptate Biotherapeutics
HQ: Canada
Website
- Description: Provider of antibodies designed to modulate gamma delta T cells in situ.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Adaptate Biotherapeutics company profile →
Vaccinex
HQ: United States
Website
- Description: Provider of therapeutic antibody discovery and development focused on neurodegeneration, oncology and autoimmune diseases. Offers Pepinemab, a monoclonal antibody targeting SEMA4D in clinical trials for cancers, Huntington's and Alzheimer's; ActivMAb, a platform for antibody discovery against complex antigens; and VX5/5261, a CXCL13-targeting antibody in preclinical development for rheumatoid arthritis and multiple sclerosis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vaccinex company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for RhoVac
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to RhoVac
2.2 - Growth funds investing in similar companies to RhoVac
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for RhoVac
4.2 - Public trading comparable groups for RhoVac
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →